Protagonist Therapeutics, Inc Restructuring Charges
Protagonist Therapeutics, Inc (PTGX) reported Restructuring Charges of $300.00 thousand for the 3-month period ending 2020-09-30, per its 10-Q filed 2021-11-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2022-02-28
- Protagonist Therapeutics, Inc restructuring charges for the quarter ending 2020-09-30 was $300.00K.
- Protagonist Therapeutics, Inc restructuring charges for the quarter ending 2020-06-30 was $300.00K.
| Period end | Restructuring Charges | Restructuring Charges 3 month | Restructuring Charges 6 month |
|---|---|---|---|
| 2020-09-30 | $300.00K 10-Q · filed 2021-11-03 | $600.00K derived: sum of 2 quarters · filed 2021-11-03 | |
| 2020-06-30 | $300.00K 10-Q · filed 2021-08-04 | ||
| 2020-05-07 | $300.00K 10-Q · filed 2020-11-04 | ||
| 2020-03-07 | $300.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |